Sinocelltech Group Ltd (688520) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Sinocelltech Group Ltd ¥4.36, price ¥37.05, upside -88.2%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sinocelltech Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥31.32 – ¥94.27 · fair‑value band ¥2.14 – ¥6.76 · the ¥37.05 price screens above the ¥4.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Sinocelltech Group in your weekly email
Every Wednesday you see whether Sinocelltech Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China.
Show more
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
Stock analysis
Sinocelltech Group Ltd (688520) currently trades at ¥37.05, while our model-based Fair Value estimate is ¥4.36, 88.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: ¥2.14 (bear) to ¥6.76 (bull), the price of ¥37.05 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sinocelltech Group Ltd reported revenue of 1.6B CNY in FY2025 versus 134M CNY in FY2021, a compound +84.6%/yr. Reported net income was −553M CNY in FY2025.
Key figures
Market cap 18.3B CNY (≈ $2.7B) · P/S ratio 13.4 · EPS (TTM) ¥−1.86 · Dividend yield 0.6% · Net margin −35.5% · Return on equity −157% · Return on assets (EBIT) −13.8% · Operating margin −36.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, 688520 screens richer than that median.
Fair Value models
Bear ¥2.14Fair Value ¥4.36Bull ¥6.76
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−37.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.0%
’16
’17
’18
’19
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−217,561.4% (2020) → −27.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside−88.2% · Bottom 25%
Profitability
Return on assets−9.8% · Above median
Net margin (TTM)−59.0% · Bottom 25%
Operating margin (TTM)−36.7% · Bottom 25%
Growth and dividend
Revenue growth−37.8% · Bottom 25%
Dividend yield (TTM)0.6% · Below median
Balance sheet
Debt / equity6.22× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B21.24× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)2.00× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)12· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sinocelltech Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688520
Frequently asked questions
Is Sinocelltech Group Ltd (688520) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥4.36 versus a price of ¥37.05, about −88% upside (overvalued).
What is the fair value of 688520?
Our model-based fair value for Sinocelltech Group Ltd is ¥4.36 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥37.05.
What is the quality score of 688520?
Sinocelltech Group Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinocelltech Group Ltd (688520)?
Our model-based price target is the fair value of ¥4.36 (as of Sep 24, 2026) from 3 valuation models. Cautious scenario ¥2.14, optimistic scenario ¥6.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinocelltech Group Ltd stock forecast for 2026?
Our models put fair value at ¥4.36, about −88% upside versus a price of ¥37.05 (overvalued). Cautious scenario ¥2.14, optimistic scenario ¥6.76. The calculation is refreshed regularly with new filings.
What is the revenue of Sinocelltech Group Ltd (688520)?
Sinocelltech Group Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Sep 24, 2026).
Does Sinocelltech Group Ltd pay a dividend?
Sinocelltech Group Ltd currently shows a dividend yield of about 0.61% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Sinocelltech Group Ltd (688520)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinocelltech Group Ltd it is ¥4.36 per share (as of Sep 24, 2026), against a price of ¥37.05. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Sinocelltech Group Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688520 trades above its calculated fair value: price ¥37.05, fair value ¥4.36, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688520?
No. The price is what the market pays today (¥37.05); the fair value is what the company's own numbers justify (¥4.36). For Sinocelltech Group Ltd the two are ¥32.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinocelltech Group Ltd worth?
The market values Sinocelltech Group Ltd at about 18.3B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥37.05; our models calculate a fair value of ¥4.36 per share.
What do the bullish and bearish scenarios say about 688520?
Our models span a range for Sinocelltech Group Ltd: cautious scenario ¥2.14, base ¥4.36, optimistic ¥6.76 per share (as of Sep 24, 2026, price ¥37.05). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sinocelltech Group Ltd (688520)?
Balance-sheet figures for Sinocelltech Group Ltd (as of Sep 24, 2026): return on equity −157.2%, debt of 6.22 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 688520 from its 52-week high?
Sinocelltech Group Ltd trades at ¥37.05, about 34% below its 52-week high of ¥56.38 and 16% above the low of ¥32.00 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.36 is for.
Which stocks are comparable to Sinocelltech Group Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinocelltech Group Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price ¥37.05, calculated fair value ¥4.36 (−88%), Quality Score 25/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688520 calculated?
We run Sinocelltech Group Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥4.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sinocelltech Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinocelltech Group Ltd (688520)?
The closing price on Sep 30, 2026 was ¥37.05. Our model-based fair value is ¥4.36, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinocelltech Group Ltd right now?
The price sits above even our optimistic bull case (¥6.76). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥2.14 to ¥6.76). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Sinocelltech Group Ltd
How large is the market capitalisation of Sinocelltech Group Ltd (688520)?
The market capitalisation of Sinocelltech Group Ltd is 18.3B CNY (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinocelltech Group Ltd (688520)?
The price-to-sales ratio of Sinocelltech Group Ltd is 13.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinocelltech Group Ltd (688520)?
Earnings per share at Sinocelltech Group Ltd are ¥−1.86. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sinocelltech Group Ltd (688520)?
The dividend yield of Sinocelltech Group Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinocelltech Group Ltd (688520)?
The net margin of Sinocelltech Group Ltd is −35.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinocelltech Group Ltd (688520)?
The return on equity (ROE) of Sinocelltech Group Ltd is −157% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinocelltech Group Ltd (688520)?
On an EBIT basis the return on assets of Sinocelltech Group Ltd is −13.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinocelltech Group Ltd (688520)?
The operating margin of Sinocelltech Group Ltd is −36.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinocelltech Group Ltd (688520)?
Revenue at Sinocelltech Group Ltd is growing −37.8% versus a year earlier (3y avg +15.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinocelltech Group Ltd (688520)?
Earnings per share at Sinocelltech Group Ltd are growing −23.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sinocelltech Group Ltd (688520) generate?
The free cash flow of Sinocelltech Group Ltd is −492M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sinocelltech Group Ltd (688520) carry?
The net debt of Sinocelltech Group Ltd is 1.8B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sinocelltech Group Ltd in the live analysis
One click puts Sinocelltech Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
